Your browser is no longer supported. Please, upgrade your browser.
Settings
ADRO Aduro BioTech, Inc. daily Stock Chart
ADRO [NASD]
Aduro BioTech, Inc.
Index- P/E- EPS (ttm)-1.36 Insider Own1.20% Shs Outstand78.57M Perf Week1.39%
Market Cap573.56M Forward P/E- EPS next Y-1.33 Insider Trans-38.48% Shs Float49.00M Perf Month-9.32%
Income-95.30M PEG- EPS next Q-0.36 Inst Own51.50% Short Float12.49% Perf Quarter-23.56%
Sales17.40M P/S32.96 EPS this Y-59.40% Inst Trans0.92% Short Ratio12.19 Perf Half Y-46.72%
Book/sh3.41 P/B2.14 EPS next Y-0.80% ROA-21.10% Target Price15.10 Perf Year-33.64%
Cash/sh4.40 P/C1.66 EPS next 5Y-1.10% ROE-39.30% 52W Range6.01 - 14.05 Perf YTD-2.67%
Dividend- P/FCF- EPS past 5Y- ROI-41.10% 52W High-48.04% Beta-
Dividend %- Quick Ratio10.60 Sales past 5Y- Gross Margin- 52W Low21.57% ATR0.39
Employees173 Current Ratio10.60 Sales Q/Q0.00% Oper. Margin- RSI (14)43.18 Volatility5.48% 5.09%
OptionableYes Debt/Eq0.00 EPS Q/Q39.40% Profit Margin- Rel Volume1.27 Prev Close6.90
ShortableYes LT Debt/Eq0.00 EarningsJan 30 BMO Payout- Avg Volume502.16K Price7.30
Recom1.70 SMA20-3.02% SMA50-10.02% SMA200-27.33% Volume637,524 Change5.80%
Dec-13-17Reiterated H.C. Wainwright Buy $18 → $9.50
May-01-17Initiated Rodman & Renshaw Buy $18
May-17-16Reiterated FBR Capital Outperform $30 → $22
Mar-15-16Downgrade BofA/Merrill Buy → Underperform $32 → $14
Mar-02-16Initiated FBR Capital Outperform $30
Dec-01-15Downgrade Oppenheimer Outperform → Perform
Nov-24-15Reiterated ROTH Capital Buy $74 → $68
Oct-20-15Initiated Oppenheimer Outperform $30
May-11-15Initiated Leerink Partners Outperform $48
May-11-15Initiated Canaccord Genuity Buy $43
May-11-15Initiated BofA/Merrill Buy $40
Apr-20-15Initiated ROTH Capital Buy $74
Jan-05-18 08:00AM  Aduro Biotech Announces Management Changes GlobeNewswire
07:30AM  Report: Developing Opportunities within Aduro Biotech, Progenics Pharmaceuticals, Gevo, OSI, Senseonics, and Donnelley Financial Solutions Future Expectations, Projections Moving into 2018 GlobeNewswire
Jan-04-18 04:01PM  Aduro Biotech to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire +5.41%
Dec-29-17 11:26AM  ETFs with exposure to Aduro BioTech, Inc. : December 29, 2017 Capital Cube
Dec-20-17 08:00AM  Aduro Biotech Expands Leading Intellectual Property Position in STING Field with Newly Issued Patent GlobeNewswire
Dec-18-17 02:22PM  ETFs with exposure to Aduro BioTech, Inc. : December 18, 2017 Capital Cube
08:00AM  Aduro Biotech Announces the Initiation of a Phase 1/2 Clinical Trial of BION-1301, a Novel Anti-APRIL Antibody, for the Treatment of Multiple Myeloma GlobeNewswire
Dec-12-17 08:00AM  Aduro Biotech Provides Update on CRS-207 Programs GlobeNewswire +5.10%
Dec-11-17 04:01PM  Aduro Biotech to Host a Program Update Call GlobeNewswire
Dec-04-17 11:15AM  Aduro BioTech, Inc. Value Analysis (NASDAQ:ADRO) : December 4, 2017 Capital Cube -5.24%
Dec-01-17 07:13AM  Aduro BioTech, Inc. breached its 50 day moving average in a Bullish Manner : ADRO-US : December 1, 2017 Capital Cube
Nov-29-17 10:46AM  ETFs with exposure to Aduro BioTech, Inc. : November 29, 2017 Capital Cube +5.14%
Nov-21-17 01:00AM  Aduro Biotech Scientific Advisor and Co-Founder of Aduro Biotech Europe Wiebe Olijve Honored with Royal Decoration GlobeNewswire
Nov-16-17 11:04AM  ETFs with exposure to Aduro BioTech, Inc. : November 16, 2017 Capital Cube
Nov-10-17 08:00AM  Aduro Biotech Announces Promising Preclinical Data that Validate Anti-CTLA-4 Antibody ADU-1604 GlobeNewswire
Nov-06-17 06:50PM  Coal demand in Indonesia is on the upswing: executive CNBC Videos
11:00AM  ETFs with exposure to Aduro BioTech, Inc. : November 6, 2017 Capital Cube
Nov-02-17 09:15AM  Aduro BioTech, Inc. :ADRO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 2, 2017 Capital Cube
Nov-01-17 09:05AM  Aduro Biotech Announces Upcoming Data Presentations at the 59th American Society of Hematology Annual Meeting GlobeNewswire -5.03%
Oct-31-17 06:26PM  Aduro Biotech reports 3Q loss Associated Press
04:01PM  Aduro Biotech Reports Third Quarter 2017 Financial Results GlobeNewswire
Oct-25-17 09:46AM  ETFs with exposure to Aduro BioTech, Inc. : October 25, 2017 Capital Cube
Oct-17-17 08:00AM  Aduro Biotech Announces Presentation of Phase 1 Data for LADD-based Immunotherapy at World Conference on Lung Cancer GlobeNewswire
Oct-09-17 08:00AM  Aduro Biotech Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancers 32nd Annual Meeting GlobeNewswire
Sep-27-17 08:01AM  Aduro Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD Based on Proprietary Neoantigen Technology GlobeNewswire
Sep-26-17 08:01AM  Aduro Biotech Announces Advancement of ADU-S100 into Global Combination Trial With PDR001 for the Treatment of Solid Tumors and Lymphomas GlobeNewswire
Sep-18-17 04:02PM  Aduro Biotech to Present at Three Investor Conferences in the Second Half of September GlobeNewswire
Sep-08-17 02:45AM  Why Is Aduro Biotech (ADRO) Down 6.8% Since the Last Earnings Report? Zacks
Sep-07-17 12:05PM  ETFs with exposure to Aduro BioTech, Inc. : September 7, 2017 Capital Cube
Sep-06-17 08:25AM  Aduro BioTech, Inc. :ADRO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 6, 2017 Capital Cube
Sep-01-17 09:56AM  Aduro BioTech, Inc. breached its 50 day moving average in a Bullish Manner : ADRO-US : September 1, 2017 Capital Cube
Aug-31-17 04:05PM  Aduro Biotech to Present at Three Investor Conferences in the First Half of September GlobeNewswire
Aug-23-17 05:09PM  Aduro BioTech, Inc. Value Analysis (NASDAQ:ADRO) : August 23, 2017 Capital Cube
Aug-11-17 10:11AM  Aduro BioTech, Inc. breached its 50 day moving average in a Bearish Manner : ADRO-US : August 11, 2017 Capital Cube
Aug-09-17 08:00AM  Aduro Biotech Bolsters Intellectual Property Position in STING Field with Two New Patents GlobeNewswire
Aug-03-17 04:08PM  Aduro (ADRO) Q2 Loss Narrower than Expected, Revenues Top Zacks -5.56%
04:05PM  Aduro Biotech to Present at the 37th Annual Canaccord Genuity Growth Conference GlobeNewswire
Aug-02-17 10:54PM  Aduro Biotech reports 2Q loss Associated Press
04:01PM  Aduro Biotech Reports Second Quarter 2017 Financial Results GlobeNewswire
Jul-27-17 08:00AM  Aduro Biotech Announces Andrea van Elsas, Ph.D., to be Named Chief Scientific Officer Effective September 1, 2017 GlobeNewswire
Jul-13-17 08:00AM  Aduro Announces Milestone Achieved Relating to Collaboration with Merck for Development of Anti-CD27 Antibody for the Treatment of Cancer GlobeNewswire
Jul-07-17 08:20AM  Verastem (VSTM) Shows Strength: Stock Adds 42% in Session Zacks
Jun-29-17 04:05PM  Aduro Biotech Announces Initiation of Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Previously-Treated Gastroesophageal Adenocarcinoma GlobeNewswire
09:47AM  Aduro Starts Phase II Combo Study with CRS-207 & Keytruda Zacks
Jun-28-17 04:05PM  Aduro Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Previously Treated Malignant Pleural Mesothelioma GlobeNewswire
Jun-14-17 08:46AM  Can Aduro BioTech (ADRO) Run Higher on Strong Earnings Estimate Revisions? Zacks
Jun-01-17 08:05AM  Aduro Biotech Announces FDA Clearance of Investigational New Drug Application to Evaluate the Combination of ADU-S100 with PDR001 for the Treatment of Solid Tumors and Lymphomas GlobeNewswire
May-26-17 07:05AM  Aduro Biotech to Host and Webcast an Investor Event in Conjunction with the 2017 ASCO Annual Meeting GlobeNewswire
May-17-17 03:18PM  Aduro Biotech, Merck Team on Cancer Drug Trial TheStreet.com
09:05AM  Aduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduros CRS-207 with Mercks KEYTRUDA® (Pembrolizumab) for the Treatment of Mesothelioma GlobeNewswire
May-05-17 03:46PM  ETFs with exposure to Aduro BioTech, Inc. : May 5, 2017 Capital Cube
May-04-17 10:08AM  Aduro BioTech, Inc. :ADRO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017 Capital Cube
May-02-17 07:01PM  Aduro Biotech reports 1Q loss Associated Press
04:05PM  Aduro Biotech Reports First Quarter 2017 Financial Results GlobeNewswire
Apr-25-17 08:00AM  Aduro Biotech to Present at Two Investor Conferences in May GlobeNewswire
Apr-20-17 04:05PM  Aduro Biotech Announces Management Promotions GlobeNewswire
Apr-05-17 04:14PM  ETFs with exposure to Aduro BioTech, Inc. : April 5, 2017 Capital Cube
Apr-03-17 02:28AM  Why Is Aduro (ADRO) Down 3.6% Since the Last Earnings Report? Zacks -8.84%
Mar-27-17 10:00AM  Aduro Biotech, Inc. (Nasdaq: ADRO) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
Mar-17-17 11:58AM  Aduro BioTech, Inc. :ADRO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Capital Cube
Mar-16-17 10:18AM  Aduro BioTech, Inc. :ADRO-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017 Capital Cube
Mar-15-17 09:00AM  Aduro Biotech to Host Research and Development Day in New York GlobeNewswire
Mar-10-17 09:00AM  Aduro Biotech Awarded East Bay Innovation Award for its Contributions in Life Sciences and the San Francisco East Bay Community GlobeNewswire
Mar-08-17 01:04PM  ADURO BIOTECH, INC. Financials
Mar-06-17 04:05PM  Aduro Biotech Announces Upcoming Data Presentations at the 2017 American Association for Cancer Research Annual Meeting GlobeNewswire
Mar-03-17 08:22AM  Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4 Zacks
Mar-02-17 04:05PM  Aduro Biotech Announces Upcoming Data Presentations at the Keystone Symposia on Cancer Immunology and Immunotherapy Conference GlobeNewswire
Mar-01-17 05:27PM  Aduro Biotech reports 4Q loss
04:34PM  ADURO BIOTECH, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib
04:27PM  ADURO BIOTECH, INC. Files SEC form 10-K, Annual Report
04:05PM  Aduro Biotech Announces Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Feb-28-17 08:00AM  Aduro Biotech to Present at Two Investor Conferences in March GlobeNewswire
Feb-10-17 08:00AM  Aduro Biotech to Present at the Leerink Partners 6th Annual Global Healthcare Conference GlobeNewswire
Feb-01-17 07:28AM  Aduro BioTech, Inc. breached its 50 day moving average in a Bullish Manner : ADRO-US : February 1, 2017
Jan-26-17 08:00AM  Aduro Biotech Announces Appointment of Leading Immunotherapy and Oncology Experts to Scientific Advisory Board GlobeNewswire
Jan-20-17 08:39AM  Aduro (ADRO) Inks License Agreement with Stanford University
Jan-19-17 08:00AM  Aduro Biotech Enters into Exclusive License Agreement for Proprietary Neoantigen Identification Technology GlobeNewswire
Jan-17-17 10:35AM  ETFs with exposure to Aduro BioTech, Inc. : January 17, 2017
Jan-16-17 07:40AM  Aduro BioTech, Inc. breached its 50 day moving average in a Bullish Manner : ADRO-US : January 16, 2017
Jan-09-17 10:24AM  Aduro BioTech, Inc. Value Analysis (NASDAQ:ADRO) : January 9, 2017
09:04AM  ADURO BIOTECH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  Aduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduros CRS-207 with Mercks KEYTRUDA® (pembrolizumab) for the Treatment of Gastric Cancer GlobeNewswire
Jan-06-17 07:37AM  Aduro BioTech, Inc. breached its 50 day moving average in a Bullish Manner : ADRO-US : January 6, 2017
Dec-27-16 04:00PM  Aduro Biotech to Present at the 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-15-16 04:30PM  ADURO BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
01:19AM  Is Aduro BioTech Inc (ADRO) A Good Stock To Buy? at Insider Monkey
Dec-06-16 05:00AM  Aduro Biotech Europes Hans van Eenennaam, Ph.D. and John Dulos, Ph.D. Honored with the Intellectual Property Owners Education Foundations 43rd Inventor of the Year Award for Contributions in the Discovery of KEYTRUDA® (pembrolizumab) GlobeNewswire
Dec-05-16 08:30AM  Aduro Biotech Inc to Provide Update on Anti-CD27 Agonist Call scheduled for 8:30 am ET today +6.48%
04:00AM  Aduro Biotech Announces Anti-CD27 Agonist, an Investigational Anti-Cancer Immunotherapy, Advancing in Collaboration with MSD GlobeNewswire
Dec-03-16 12:00PM  Aduro Biotech Presents Preclinical Data Supporting Clinical Development of its Anti-APRIL Antibody, BION-1301, for the Treatment of Multiple Myeloma GlobeNewswire
Nov-30-16 11:59AM  ETFs with exposure to Aduro BioTech, Inc. : November 30, 2016 -8.06%
Nov-29-16 07:27AM  Aduro BioTech, Inc. breached its 50 day moving average in a Bearish Manner : ADRO-US : November 29, 2016
Nov-24-16 07:45PM  Aduro Cancer Vaccine Emerges From FDA Hold (ADRO) at Investopedia
Nov-22-16 08:58AM  Aduro Reports Partial Hold Lift on LADD Studies in U.S.
08:46AM  Is Aduro BioTech (ADRO) Stock A Solid Choice Right Now?
Nov-21-16 08:06AM  ADURO BIOTECH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  Partial Clinical Hold Lifted and Enrollment Resumes for Aduro Biotech LADD Clinical Trials GlobeNewswire
Nov-18-16 11:21AM  Aduro BioTech (ADRO) Shares March Higher, Can It Continue?
09:50AM  Aduro BioTech, Inc. :ADRO-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016
Nov-12-16 08:00AM  Aduro Biotech Highlights Positive Clinical Results from Second Cohort of Phase 1b Mesothelioma Clinical Trial GlobeNewswire
Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases. It is developing CRS-207, which has completed Phase Ib clinical trials for the treatment of unresectable malignant pleural mesothelioma; that has completed Phase II clinical trials for the treatment of pancreatic cancer; and that is in Phase I/II clinical trials for the treatment of ovarian cancer. The company is also developing ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; ADU-741, which is in Phase I clinical trials for the treatment of prostate cancer; and a product candidate for the treatment of patients with cancers of the gastrointestinal tract. In addition, it is developing STING Pathway Activator product candidates that are synthetic small molecule immune modulators, which target and activate Stimulator of Interferon Genes receptor under collaboration with Novartis Pharmaceuticals Corporation; and product candidates that address other therapeutic areas, such as autoimmune and infectious diseases. Further, the company's products pipeline comprises BION-1301, a B-select mAb novel therapy for multiple myeloma; and antibody product candidates, including APRIL for the treatment of multiple myeloma, as well as oncology therapies, such as CD27, PD-1, and CTLA-4. Aduro BioTech, Inc. has development and commercialization agreement with Genmab to evaluate five bispecific antibody product candidates targeting immune checkpoints; and collaboration agreement with Janssen Biotech, Inc. and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is headquartered in Berkeley, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ISAACS STEPHEN TPresident and CEOJan 05Option Exercise0.457,9493,577213,695Jan 09 05:48 PM
ISAACS STEPHEN TPresident and CEOJan 05Sale7.957,94963,195205,746Jan 09 05:48 PM
SCHAFER GREGORY WChief Operating OfficerJan 02Option Exercise1.0420,00020,767210,745Jan 03 06:59 PM
SCHAFER GREGORY WChief Operating OfficerJan 02Sale7.6120,000152,142190,745Jan 03 06:59 PM
SCHAFER GREGORY WChief Operating OfficerDec 29Option Exercise0.8242,00034,440190,745Jan 03 06:59 PM
Brockstedt Dirk G.EVP of Research and Dev.Dec 29Option Exercise1.4552,00075,400124,603Jan 03 07:03 PM
Templeman BlaineExecutive VP, General CounselDec 18Sale8.252,88423,79369,937Dec 20 06:52 PM
Brockstedt Dirk G.EVP of Research and Dev.Dec 15Option Exercise1.4564,10892,957137,826Dec 15 08:02 PM
Brockstedt Dirk G.EVP of Research and Dev.Dec 15Sale8.1165,223529,18772,603Dec 15 08:02 PM
Brockstedt Dirk G.EVP of Research and Dev.Dec 01Option Exercise0.5210,0005,20083,718Dec 04 07:59 PM
ISAACS STEPHEN TPresident and CEODec 01Option Exercise0.4540,00018,000213,921Dec 04 07:53 PM
SCHAFER GREGORY WChief Operating OfficerDec 01Option Exercise1.0420,00020,767168,745Dec 04 07:56 PM
Lew JenniferSr. Vice President of FinanceDec 01Option Exercise0.826,6005,41268,938Dec 04 07:57 PM
SCHAFER GREGORY WChief Operating OfficerDec 01Sale9.3420,000186,882148,745Dec 04 07:56 PM
ISAACS STEPHEN TPresident and CEODec 01Sale9.3840,000375,028173,921Dec 04 07:53 PM
Brockstedt Dirk G.EVP of Research and Dev.Dec 01Sale9.4010,00093,99873,718Dec 04 07:59 PM
Lew JenniferSr. Vice President of FinanceDec 01Sale9.466,60062,43362,338Dec 04 07:57 PM
Templeman BlaineExecutive VP, General CounselNov 17Sale8.852432,15158,834Nov 17 06:43 PM
Lew JenniferSr. Vice President of FinanceNov 15Option Exercise0.826,6005,41268,938Nov 17 06:42 PM
Lew JenniferSr. Vice President of FinanceNov 15Sale8.956,60059,07062,338Nov 17 06:42 PM
Brockstedt Dirk G.EVP of Research and Dev.Nov 13Option Exercise0.524,0622,11277,780Nov 14 06:09 PM
ISAACS STEPHEN TPresident and CEONov 13Option Exercise0.453,4001,530177,321Nov 14 06:20 PM
Brockstedt Dirk G.EVP of Research and Dev.Nov 13Sale8.004,06232,49673,718Nov 14 06:09 PM
ISAACS STEPHEN TPresident and CEONov 13Sale8.003,40027,215173,921Nov 14 06:20 PM
Brockstedt Dirk G.EVP of Research and Dev.Nov 10Option Exercise0.521,81594475,533Nov 14 06:09 PM
ISAACS STEPHEN TPresident and CEONov 10Option Exercise0.4516,4007,380190,321Nov 14 06:20 PM
Brockstedt Dirk G.EVP of Research and Dev.Nov 10Sale8.011,81514,54473,718Nov 14 06:09 PM
ISAACS STEPHEN TPresident and CEONov 10Sale7.9616,400130,508173,921Nov 14 06:20 PM
ISAACS STEPHEN TPresident and CEONov 07Option Exercise0.453,8001,710177,721Nov 08 07:56 PM
ISAACS STEPHEN TPresident and CEONov 07Sale7.953,80030,223173,921Nov 08 07:56 PM
ISAACS STEPHEN TPresident and CEONov 06Option Exercise0.4516,4007,380190,321Nov 08 07:56 PM
Brockstedt Dirk G.EVP of Research and Dev.Nov 06Option Exercise0.524,1232,14477,841Nov 08 07:59 PM
SCHAFER GREGORY WChief Operating OfficerNov 06Option Exercise1.0420,00020,767168,745Nov 08 08:01 PM
SCHAFER GREGORY WChief Operating OfficerNov 06Sale7.9720,000159,312148,745Nov 08 08:01 PM
Brockstedt Dirk G.EVP of Research and Dev.Nov 06Sale8.044,12333,13273,718Nov 08 07:59 PM
ISAACS STEPHEN TPresident and CEONov 06Sale7.9816,400130,934173,921Nov 08 07:56 PM
SCHAFER GREGORY WChief Operating OfficerOct 02Option Exercise1.3620,00027,148168,745Oct 04 08:26 PM
Brockstedt Dirk G.EVP of Research and Dev.Oct 02Option Exercise0.5210,0005,20083,718Oct 04 08:31 PM
Lew JenniferSr. Vice President of FinanceOct 02Option Exercise0.826,6005,41268,938Oct 04 08:21 PM
ISAACS STEPHEN TPresident and CEOOct 02Option Exercise0.4540,00018,000213,921Oct 04 08:23 PM
Lew JenniferSr. Vice President of FinanceOct 02Sale10.616,60069,99562,338Oct 04 08:21 PM
SCHAFER GREGORY WChief Operating OfficerOct 02Sale10.7520,000215,060148,745Oct 04 08:26 PM
ISAACS STEPHEN TPresident and CEOOct 02Sale10.7840,000431,032173,921Oct 04 08:23 PM
Brockstedt Dirk G.EVP of Research and Dev.Oct 02Sale10.5910,000105,87073,718Oct 04 08:31 PM
Templeman BlaineExecutive VP, General CounselSep 18Sale11.202,88432,30158,834Sep 20 07:11 PM
ISAACS STEPHEN TPresident and CEOSep 13Sale10.9912,204134,071173,921Sep 14 09:25 PM
SCHAFER GREGORY WChief Operating OfficerSep 13Sale10.994,85953,380148,745Sep 14 09:24 PM
Brockstedt Dirk G.EVP of Research and Dev.Sep 13Sale10.993,55739,07673,718Sep 14 09:22 PM
Lew JenniferSr. Vice President of FinanceSep 13Sale10.993,55739,07662,338Sep 14 09:21 PM
van Elsas AndreaChief Scientific OfficerSep 13Sale10.994,92254,072207,231Sep 14 09:20 PM
Templeman BlaineExecutive VP, General CounselSep 13Sale10.993,55739,07661,718Sep 14 09:19 PM
Brockstedt Dirk G.EVP of Research and Dev.Sep 01Option Exercise0.5210,0005,20059,300Sep 06 04:27 PM
ISAACS STEPHEN TPresident and CEOSep 01Option Exercise0.4540,00018,000144,025Sep 06 04:28 PM
Lew JenniferSr. Vice President of FinanceSep 01Option Exercise0.826,6005,41249,195Sep 06 04:29 PM
SCHAFER GREGORY WChief Operating OfficerSep 01Option Exercise1.2420,00024,800140,979Sep 06 04:30 PM
Sacks NatalieChief Medical OfficerSep 01Sale11.714,88557,19645,115Sep 06 04:32 PM
SCHAFER GREGORY WChief Operating OfficerSep 01Sale11.7020,000233,980120,979Sep 06 04:30 PM
Lew JenniferSr. Vice President of FinanceSep 01Sale11.706,60077,24242,595Sep 06 04:29 PM
ISAACS STEPHEN TPresident and CEOSep 01Sale11.7140,000468,596104,025Sep 06 04:28 PM
Brockstedt Dirk G.EVP of Research and Dev.Sep 01Sale11.6910,000116,94849,300Sep 06 04:27 PM
Dubensky Thomas W.Chief Scientific OfficerAug 11Option Exercise1.009,0889,08848,988Aug 11 08:03 PM
Dubensky Thomas W.Chief Scientific OfficerAug 11Sale11.179,088101,53839,900Aug 11 08:03 PM
Dubensky Thomas W.Chief Scientific OfficerAug 10Option Exercise1.0040,91240,91280,812Aug 11 08:03 PM
Dubensky Thomas W.Chief Scientific OfficerAug 10Sale11.4340,912467,66539,900Aug 11 08:03 PM
SCHAFER GREGORY WChief Operating OfficerAug 08Option Exercise1.2714,18918,004135,168Aug 09 07:45 PM
SCHAFER GREGORY WChief Operating OfficerAug 08Sale12.1614,189172,550120,979Aug 09 07:45 PM
ISAACS STEPHEN TPresident and CEOAug 07Option Exercise0.4540,00018,000144,025Aug 09 07:46 PM
Lew JenniferSr. Vice President of FinanceAug 07Option Exercise0.826,6005,41249,195Aug 09 07:41 PM
Brockstedt Dirk G.EVP of Research and Dev.Aug 07Option Exercise0.5210,0005,20059,300Aug 09 07:44 PM
SCHAFER GREGORY WChief Operating OfficerAug 07Option Exercise1.2225,81131,616146,790Aug 09 07:45 PM
Brockstedt Dirk G.EVP of Research and Dev.Aug 07Sale12.1810,000121,79549,300Aug 09 07:44 PM
Lew JenniferSr. Vice President of FinanceAug 07Sale12.176,60080,29042,595Aug 09 07:41 PM
SCHAFER GREGORY WChief Operating OfficerAug 07Sale12.1725,811314,233120,979Aug 09 07:45 PM
ISAACS STEPHEN TPresident and CEOAug 07Sale12.1940,000487,564104,025Aug 09 07:46 PM
Dubensky Thomas W.Chief Scientific OfficerJul 06Option Exercise0.524,5122,34644,412Jul 06 07:10 PM
Dubensky Thomas W.Chief Scientific OfficerJul 06Sale11.234,51250,67339,900Jul 06 07:10 PM
Dubensky Thomas W.Chief Scientific OfficerJul 05Option Exercise0.5233,68817,51873,588Jul 06 07:10 PM
Dubensky Thomas W.Chief Scientific OfficerJul 05Sale11.4633,688385,93639,900Jul 06 07:10 PM
ISAACS STEPHEN TPresident and CEOJul 05Sale11.011,34114,763104,025Jul 06 07:12 PM
Dubensky Thomas W.Chief Scientific OfficerJul 03Option Exercise0.5211,8006,13651,700Jul 06 07:10 PM
ISAACS STEPHEN TPresident and CEOJul 03Option Exercise0.5040,00019,965144,025Jul 06 07:12 PM
Brockstedt Dirk G.EVP of Research and Dev.Jul 03Option Exercise0.4810,0004,82659,300Jul 06 07:11 PM
Lew JenniferSr. Vice President of FinanceJul 03Option Exercise0.8212,0009,84054,595Jul 06 07:13 PM
ISAACS STEPHEN TPresident and CEOJul 03Sale11.0638,659427,634105,366Jul 06 07:12 PM
Brockstedt Dirk G.EVP of Research and Dev.Jul 03Sale11.0210,000110,16749,300Jul 06 07:11 PM
Dubensky Thomas W.Chief Scientific OfficerJul 03Sale11.0211,800130,02839,900Jul 06 07:10 PM
Lew JenniferSr. Vice President of FinanceJul 03Sale11.1412,000133,63242,595Jul 06 07:13 PM
Lew JenniferSr. Vice President of FinanceJun 28Option Exercise0.8212,0009,84054,595Jun 30 06:03 PM
SCHAFER GREGORY WChief Operating OfficerJun 28Option Exercise1.4540,00058,000160,979Jun 30 06:01 PM
Lew JenniferSr. Vice President of FinanceJun 28Sale11.1912,000134,23642,595Jun 30 06:03 PM
SCHAFER GREGORY WChief Operating OfficerJun 28Sale11.2640,000450,568120,979Jun 30 06:01 PM
ISAACS STEPHEN TPresident and CEOJun 19Option Exercise0.5240,00020,800144,025Jun 21 06:56 PM
ISAACS STEPHEN TPresident and CEOJun 19Sale10.5040,000420,164104,025Jun 21 06:56 PM
Dubensky Thomas W.Chief Scientific OfficerJun 05Option Exercise0.5217,5779,14057,477Jun 05 07:25 PM
Dubensky Thomas W.Chief Scientific OfficerJun 05Sale9.9917,577175,62839,900Jun 05 07:25 PM
Dubensky Thomas W.Chief Scientific OfficerJun 02Option Exercise0.5248,75325,35288,653Jun 05 07:25 PM
Dubensky Thomas W.Chief Scientific OfficerJun 02Sale10.1048,753492,28339,900Jun 05 07:25 PM
Brockstedt Dirk G.EVP of Research and Dev.Jun 01Option Exercise0.528,0004,16057,300Jun 05 07:22 PM
Dubensky Thomas W.Chief Scientific OfficerJun 01Option Exercise0.5277,97140,545117,871Jun 05 07:25 PM
Dubensky Thomas W.Chief Scientific OfficerJun 01Sale10.0077,971779,86639,900Jun 05 07:25 PM